Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
| ▸ | GGT1 | P19440 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3778396 | 0.91 | ALDH1A1 (0.69) | ALDH1A1HSD17B10RAB9AHPGDPKM | |
| SCHEMBL3777171 | 0.86 | SCN3A (0.64) | ALDH1A1HSD17B10MEN1KMT2AMAPT | |
| SCHEMBL3773919 | 0.86 | ALDH1A1 (0.50) | ALDH1A1HSD17B10HPGDSCN3AEPHX2 | |
| SCHEMBL3778727 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3786795 | 0.81 | ALDH1A1 (0.55) | ALDH1A1HSD17B10MEN1KMT2AMAPT | |
| SCHEMBL3786604 | 0.81 | MEN1 (0.57) | ALDH1A1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3773992 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3165768 | 0.79 | SCN3A (0.77) | ALDH1A1NPC1RAB9APKMMEN1 | |
| SCHEMBL3780349 | 0.78 | ALDH1A1 (0.60) | ALDH1A1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3786343 | 0.77 | ALDH1A1 (0.48) | ALDH1A1HSD17B10RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| EP-1937657-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | PPARD, PPARG, PPARA | ALDH1A1 1118/4885HSD17B10 877/4885NPC1 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.